Effect of High-Dose Vitamin D Supplementation on Upper Respiratory Tract Infection Symptom Severity in Healthy Children.


Journal

The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858

Informations de publication

Date de publication:
06 2019
Historique:
pubmed: 7 11 2018
medline: 1 5 2020
entrez: 7 11 2018
Statut: ppublish

Résumé

Observational studies support the role of vitamin D in reducing viral upper respiratory tract infection (URTI) symptom severity in adults and children. This study assessed whether wintertime high-dose vitamin D supplementation (2000 IU/day) reduces URTI symptom severity compared with standard-dose (400 IU/day) supplementation in preschool children. Secondary objectives were to assess effects of high-dose supplementation on outpatient physician visits, emergency department (ED) visits and antibiotic prescriptions for URTI. This was a secondary analysis of a multisite randomized clinical trial involving 703 healthy 1- to 5-year-old children in Toronto, Canada. High-dose or standard-dose oral vitamin D was randomly assigned for 1 winter season. For each URTI, parents completed symptom checklists based on the Canadian Acute Respiratory and Flu Scale. Symptom severity, frequency of outpatient visits, ED visits and antibiotic prescriptions for URTI between groups were analyzed using negative binomial regression. URTI symptom severity was not reduced in the high-dose vs. standard-dose group [incidence rate ratio (IRR) = 0.97; 95% confidence interval (CI): 0.76-1.23]. High-dose vitamin D did not decrease frequency of outpatient visits (IRR = 1.16; 95% CI: 0.84-1.60), ED visits (IRR = 1.17; 95% CI: 0.57-2.40) or antibiotic prescriptions (IRR=1.02; 95% CI: 0.61-1.72). Serum 25-hydroxyvitamin D was higher in the high-dose group (48.7 ng/mL; 95% CI: 46.9-50.5) than the standard-dose group (36.8 ng/mL; 95% CI: 35.4-38.2; P < 0.001). High-dose vitamin D supplementation did not reduce URTI symptom severity, outpatient visits, ED visits or antibiotic prescriptions relative to standard-dose. These results do not support vitamin D supplementation above the standard recommended dose for reducing URTI symptoms in children.

Sections du résumé

BACKGROUND
Observational studies support the role of vitamin D in reducing viral upper respiratory tract infection (URTI) symptom severity in adults and children. This study assessed whether wintertime high-dose vitamin D supplementation (2000 IU/day) reduces URTI symptom severity compared with standard-dose (400 IU/day) supplementation in preschool children. Secondary objectives were to assess effects of high-dose supplementation on outpatient physician visits, emergency department (ED) visits and antibiotic prescriptions for URTI.
METHODS
This was a secondary analysis of a multisite randomized clinical trial involving 703 healthy 1- to 5-year-old children in Toronto, Canada. High-dose or standard-dose oral vitamin D was randomly assigned for 1 winter season. For each URTI, parents completed symptom checklists based on the Canadian Acute Respiratory and Flu Scale. Symptom severity, frequency of outpatient visits, ED visits and antibiotic prescriptions for URTI between groups were analyzed using negative binomial regression.
RESULTS
URTI symptom severity was not reduced in the high-dose vs. standard-dose group [incidence rate ratio (IRR) = 0.97; 95% confidence interval (CI): 0.76-1.23]. High-dose vitamin D did not decrease frequency of outpatient visits (IRR = 1.16; 95% CI: 0.84-1.60), ED visits (IRR = 1.17; 95% CI: 0.57-2.40) or antibiotic prescriptions (IRR=1.02; 95% CI: 0.61-1.72). Serum 25-hydroxyvitamin D was higher in the high-dose group (48.7 ng/mL; 95% CI: 46.9-50.5) than the standard-dose group (36.8 ng/mL; 95% CI: 35.4-38.2; P < 0.001).
CONCLUSIONS
High-dose vitamin D supplementation did not reduce URTI symptom severity, outpatient visits, ED visits or antibiotic prescriptions relative to standard-dose. These results do not support vitamin D supplementation above the standard recommended dose for reducing URTI symptoms in children.

Identifiants

pubmed: 30399024
doi: 10.1097/INF.0000000000002225
doi:

Substances chimiques

Vitamin D 1406-16-2

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

564-568

Subventions

Organisme : CIHR
ID : MOP-114945
Pays : Canada

Auteurs

Katrina Hueniken (K)

From the Department of Pediatrics, Pediatric Research, St. Michael's Hospital.
Dalla Lana School of Public Health, University of Toronto.

Mary Aglipay (M)

From the Department of Pediatrics, Pediatric Research, St. Michael's Hospital.

Catherine S Birken (CS)

Pediatric Outcomes Research Team (PORT), Division of Pediatric Medicine, Department of Pediatrics, The Hospital for Sick Children.
Department of Pediatrics, Faculty of Medicine, University of Toronto.
Institute for Health Policy, Management and Evaluation, University of Toronto.
Child Health Evaluative Sciences, SickKids Research Institute, Toronto, Ontario, Canada.

Patricia C Parkin (PC)

Pediatric Outcomes Research Team (PORT), Division of Pediatric Medicine, Department of Pediatrics, The Hospital for Sick Children.
Department of Pediatrics, Faculty of Medicine, University of Toronto.
Institute for Health Policy, Management and Evaluation, University of Toronto.
Child Health Evaluative Sciences, SickKids Research Institute, Toronto, Ontario, Canada.

Mark B Loeb (MB)

Department of Pathology and Molecular Medicine, McMaster University.
Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.

Kevin E Thorpe (KE)

Dalla Lana School of Public Health, University of Toronto.
The Li Ka Shing Knowledge Institute of St. Michael's Hospital.

David W H Dai (DWH)

The Li Ka Shing Knowledge Institute of St. Michael's Hospital.

Andreas Laupacis (A)

Institute for Health Policy, Management and Evaluation, University of Toronto.
The Li Ka Shing Knowledge Institute of St. Michael's Hospital.
Institute for Clinical Evaluative Sciences, Toronto, Canada.
Faculty of Medicine, University of Toronto.

Muhammad Mamdani (M)

The Li Ka Shing Knowledge Institute of St. Michael's Hospital.

Tony Mazzulli (T)

Department of Microbiology, Mount Sinai Hospital/University Health Network.
Department of Laboratory Medicine and Pathobiology, University of Toronto.

Jonathon L Maguire (JL)

From the Department of Pediatrics, Pediatric Research, St. Michael's Hospital.
Pediatric Outcomes Research Team (PORT), Division of Pediatric Medicine, Department of Pediatrics, The Hospital for Sick Children.
Institute for Health Policy, Management and Evaluation, University of Toronto.
Child Health Evaluative Sciences, SickKids Research Institute, Toronto, Ontario, Canada.
The Li Ka Shing Knowledge Institute of St. Michael's Hospital.
Department of Nutritional Sciences, and Faculty of Medicine, University of Toronto.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH